Quantcast

Latest Histopathology Stories

2014-04-14 14:20:45

Alzheimer's disease, the primary cause of dementia in the elderly, imposes a tremendous social and economic burden on modern society. In Japan, the burden of the disease in 2050 is estimated to be a half a trillion US dollars, a figure equivalent to the government's annual revenues. Unfortunately, it has proven very difficult to develop drugs capable of ameliorating the disease. After a tremendous burst of progress in the 1990s, the pace of discoveries has slowed. Dr. Saido believes that...

New Prostate Cancer Test May Remove The Need For Painful Biopsies
2014-04-08 09:00:53

April Flowers for redOrbit.com - Your Universe Online Globally, over one million men a year have prostate tissue samples taken to check for signs of prostate cancer. This procedure can involve up to 12 large biopsy needles and has been called barbaric by Mayo Graduate School of Medicine Professor Matthew Gettman. As well, it reveals that 70 percent of the men undergoing the procedure do not have cancer. Beyond being unnecessarily painful and risky for the patient, the procedure is...

2014-03-25 08:31:05

--Funds Will Advance Novel Approach for Treatment of Alzheimer's Disease and Other Diseases of Protein Aggregation-- CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced the completion of a $17 million Series D financing from existing and new investors to advance the Company's lead candidate, NPT088, and potential next-generation compounds toward clinical trials. NPT088 has the potential to treat a wide range of neurodegenerative diseases,...

2014-03-20 12:33:23

BERLIN and BOSTON, March 20, 2014 /PRNewswire/ -- Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq(TM). This approval comes only four weeks after receiving marketing authorization for Neuraceq(TM) from the European Commission. http://photos.prnewswire.com/prnvar/20140320/NE87281LOGO Neuraceq(TM) is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with...

2014-03-17 08:28:49

SOUTH SAN FRANCISCO, Calif., March 17, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointments of two executives to its management team. Julie A. Brooks joins the company as executive vice president, general counsel and secretary; and Andy Thorson joins as executive vice president, corporate strategy and business development. "I am thrilled to welcome Julie Brooks and Andy...

2014-03-11 08:29:14

SOUTH SAN FRANCISCO, Calif., March 11, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its fourth quarter and full-year 2013 financial results after close of market on Tuesday, March 18, 2014. Following the release, Veracyte will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company's financial results and business progress. The live webcast and subsequent replay may be accessed by visiting Veracyte's website...

2014-03-05 12:27:31

LEARN Project will Track Cognitive Change in a Comparison Group of Older Individuals, and Initiate the First Tau Imaging Study in a Longitudinal Prevention Trial CHICAGO, March 5, 2014 /PRNewswire-USNewswire/ -- The Alzheimer's Association today announced its largest ever research grant - $8 million over four years - to support the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study as a companion study to the Anti-Amyloid Treatment in Asymptomatic Alzheimer's...

2014-03-03 16:25:19

-- Presentation and Webcast Scheduled for Tuesday, March 4, at 8 a.m. ET -- SOUTH SAN FRANCISCO, Calif., March 3, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced a change in the company's presentation date and time at the Cowen and Company 34(th) Annual Health Care Conference. Bonnie H. Anderson, president and chief executive officer, will present on Tuesday, March 4, 2014 at 8:00 a.m. ET in the St. Botolph room at The Boston Marriott Copley Place in Boston, Mass....

2014-02-26 23:32:28

Fatty Liver Bible & Ezra Protocol designed by Debra E is the latest program that teaches people how to lose weight and get the body they desired. A full Fatty Liver Bible & Ezra Protocol review on the site HealthReviewCenter.com indicates if this program is worth buying. Seattle, Wa (PRWEB) February 26, 2014 Fatty Liver Bible & Ezra Protocol is a new solution for fatty liver sufferers who want to take control of their health. The program also teaches them how to deal with...

2014-02-26 08:28:18

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, president and chief executive officer, will present at the Cowen and Company 34(th) Annual Health Care Conference on Wednesday, March 5, 2014 at 10 a.m. ET in Boston, Mass. The live audio webcast and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. Please connect to the website at least 15 minutes prior to...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related